Harvard Bioscience Inc (NASDAQ:HBIO)’s traded shares stood at 0.39 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $0.64, to imply a decrease of -3.33% or -$0.02 in intraday trading. The HBIO share’s 52-week high remains $4.70, putting it -634.38% down since that peak but still an impressive 6.25% since price per share fell to its 52-week low of $0.60. The company has a valuation of $28.03M, with an average of 0.47 million shares in intraday trading volume over the past 10 days and average of 302.34K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Harvard Bioscience Inc (HBIO), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give HBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.01.
Harvard Bioscience Inc (NASDAQ:HBIO) trade information
After registering a -3.33% downside in the last session, Harvard Bioscience Inc (HBIO) has traded red over the past five days. The 5-day price performance for the stock is -1.82%, and -46.09% over 30 days. With these gigs, the year-to-date price performance is -69.85%. Short interest in Harvard Bioscience Inc (NASDAQ:HBIO) saw shorts transact 0.96 million shares and set a 3.29 days time to cover.
The extremes give us $7 and $7 for target low and target high price respectively. As such, HBIO has been trading -993.75% off suggested target high and -993.75% from its likely low.
Harvard Bioscience Inc (HBIO) estimates and forecasts
The rating firms project that company’s revenue will shrink -1.68% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 20.95M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 22.65M.Earnings reports from the last fiscal year show that sales brought in 24.51M and 23.1M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -14.53% before dropping -1.94% in the following quarter.
HBIO Dividends
Harvard Bioscience Inc has its next earnings report out on 2025-Mar-11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Harvard Bioscience Inc (NASDAQ:HBIO)’s Major holders
Harvard Bioscience Inc insiders hold 7.15% of total outstanding shares, with institutional holders owning 82.23% of the shares at 88.57% float percentage. In total, 82.23% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 2.84 million shares (or 6.5519% of shares), all amounting to roughly $8.1 million.
The next major institution holding the largest number of shares is PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. with 2.77 million shares, or about 6.3752% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.9 million.
We also have Vanguard Total Stock Market Index Fund and HEARTLAND VALUE FUND as the top two Mutual Funds with the largest holdings of the Harvard Bioscience Inc (HBIO) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.26 shares. This is just over 2.86% of the total shares, with a market valuation of $0.8 million. Data from the same date shows that the other fund manager holds a little less at 1.2, or 2.72% of the shares, all valued at about 0.76 million.
